RBC Upgrades Rigel Pharmaceuticals (RIGL) to Outperform
More News related to RIGL
- Rigel to Present at BIO CEO & Investor Conference
- Rigel Pharma (RIGL) Receives Milestone Payment as Part of Cancer Treatment Collaboration
- Rigel Receives Milestone Payment from Daiichi Sankyo for Cancer Ligase Target
- Jefferies & Co Initiates/Resumes Coverage on Pharma/Biotechnology Stocks
- Morning Movers 11/23: ABIO, SEED, FIF, FNET, DDRX, JOBS Higher; BBI, CGA, BOFL, CEPH Lower
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
RBC upgrades Rigel Pharmaceuticals (Nasdaq: RIGL) from Sector Perform to Outperform. Price target increased from $9 to $11.
To see all the upgrades/downgrades on shares of RIGL, visit our Analyst Ratings page.
Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company that discovers and develops small molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
Related Categories
UpgradesStocks Mentioned
+0.50Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
